What Real Life Sciences does

Real Life Sciences (RLS) is a clinical trial anonymization and redaction technology company serving pharmaceutical sponsors and contract research organizations (CROs) that must comply with global clinical trial transparency regulations. Founded circa 2018 and headquartered in Wayne, Pennsylvania, with an operations arm in Mandaluyong, Philippines, the company was acquired by MediSpend in January 2025 and continues to operate under the RLS brand as a subsidiary. RLS's core offering is the RLS Protect platform, an NLP-based SaaS solution purpose-built for life sciences disclosure workflows; modules cover data anonymization with quantitative risk modeling (including Health Canada's 0.09 re-identification threshold and EMA Policy 0070), document redaction, and Confidential Information Management (CIM), with integrations between AI-driven redaction suggestions and CIM workflows. The platform is supported by the Anonymization Services managed services arm, a full-time delivery team that uses the proprietary technology and a documented track record of 1M+ pages and thousands of datasets processed across regulatory and voluntary submissions.

RLS monetizes through multi-year SaaS subscriptions (RLS Protect) plus hybrid managed services engagements and professional services — including regulatory meeting preparation (e.g., Health Canada PIM), methodology training, and SAS training — aligning engagement models (dedicated, pooled, or custom teams) to sponsor and CRO priorities. Primary customers are pharmaceutical sponsors handling EMA Policy 0070, Health Canada PRCI, EMA CTR/CTIS, and FDA disclosure work, with CROs as a second primary segment using RLS Protect to serve their sponsor clients; non-profit research organizations (e.g., Vivli) make up a smaller tertiary segment supported via grant-funded partnerships, including with the Bill & Melinda Gates Foundation. GTM is direct enterprise sales with relationship-based engagement across regulatory, transparency, and compliance stakeholders, complemented by a content-driven thought-leadership engine (insights blog, webinars, podcasts) and ecosystem partnerships with Citeline (data intelligence) and ClaritiDox (regulatory writing). The company holds ISO/IEC 27001:2022 certification covering product development, managed service operations, customer success and support, and application hosting, which functions as enterprise procurement gating.

Name

Real Life Sciences

Legal name

Real Life Sciences, LLC

Website

https://rlsciences.com

Company type

Private

Founded year

2018

Operating status

Acquired

Headcount range

51–100 employees

Short description

Real Life Sciences is a clinical trial anonymization and redaction technology company that provides its NLP-based RLS Protect SaaS platform and managed Anonymization Services to pharmaceutical sponsors and CROs for global regulatory disclosure compliance (EMA, Health Canada, FDA).

Ownership category

akta.pro rank

Product category

Clinical Trial Disclosure & Data Anonymization Software

NAICS

Software Publishers (513210), Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)

akta.pro secondary industries

Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

Keywords

• Clinical trial anonymization
• Regulatory disclosure software
• Document redaction solution
• Confidential information management
• Life sciences compliance

Headquarters

HQ city

Broadway

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SaaS Subscription (RLS Protect): Software-as-a-service subscription model providing access to RLS Protect platform for data and document anonymization and redaction. Customers can use the technology independently after onboarding and training.
2. Anonymization Services: Managed services offering where RLS's full-time staff handles anonymization and redaction projects on-time and on-quality. Offers flexible engagement models including dedicated resources, pooled resources, or custom team configurations.
3. Professional Services: Turnkey project management and consulting services including regulatory meeting preparation (e.g., Health Canada PIM meetings), methodology training, and SaaS training to enable client teams.

Pricing tiers

Distribution channels1 record

Marketing channels6 records

Core offering

Real Life Sciences develops and sells the RLS Protect SaaS platform for clinical trial data anonymization and document redaction, supporting pharmaceutical sponsors and CROs in complying with global transparency regulations including EMA Policy 0070, Health Canada PRCI, EMA (EU) 536/2014/CTIS, and FDA disclosures. The platform combines NLP-based quantitative risk modeling, document redaction, and confidential information management, and is paired with Anonymization Services (managed service delivery) and the RLS Reveal real-world evidence discovery platform. The portfolio serves clients ranging from small trials to large global pharma, with over one million pages and thousands of datasets processed to date.

Product overview

Real Life Sciences offers a unified platform-plus-services portfolio centered on RLS Protect, their SaaS-based anonymization and redaction solution for clinical trial disclosure. The core RLS Protect platform encompasses modules for data anonymization, document redaction, and confidential information management (CIM), all built on NLP technology. The portfolio also includes RLS Reveal, a real-world evidence discovery platform, and Anonymization Services—a managed services offering staffed by full-time experts who use the proprietary RLS Protect technology to deliver turnkey anonymization projects. The products serve pharmaceutical sponsors and CROs across regulatory disclosure requirements including Health Canada PRCI, EMA Policy 0070, EMA CTR/CTIS, and voluntary data sharing initiatives.

Differentiator

Problem solved

Functional benefit

Brands

• RLS Protect: Leading data and document anonymization and redaction solution for Sponsors and CROs who comply with transparency requirements for regulatory bodies and voluntary sharing initiatives
• RLS Reveal
• RLS Protect CIM
• RLS Protect Redaction
• Anonymization Services

Products and services

• RLS Protect RLS Protect is a SaaS-based data and document anonymization and redaction solution designed for pharmaceutical sponsors and CROs. It offers advanced quantitative risk modeling, document anonymization, and redaction capabilities supporting Health Canada PRCI, EMA Policy 0070, EMA (EU) 536/2014/CTIS, FDA disclosures, and voluntary data sharing initiatives.
• RLS Protect - Redaction Document redaction capability within the RLS Protect platform that enables organizations to efficiently redact personal and confidential information from clinical documents while maintaining compliance with transparency requirements.
• RLS Protect - Confidential Information Management (CIM) Central solution within RLS Protect for identifying, reviewing, and redacting confidential information across teams. Features include confidential asset tracking, automated approval workflows, public domain scanning, AI-driven redaction integration, and audit-ready logs to protect IP and trade secrets.
• RLS Protect - Anonymization Core anonymization module within the RLS Protect platform providing quantitative risk-based anonymization strategies for clinical trial data and documents, enabling measurement of re-identification risk and data utility for regulatory submissions.
• Anonymization Services Managed-service offering providing full-time operational staff who use proprietary RLS technology and methodology to deliver anonymization and redaction projects on-time and on-quality for sponsors and CROs. Services include project management, risk assessment, document processing, and regulatory submission support, with flexible engagement models (dedicated, pooled, or custom teams).
• RLS Reveal Real-world data/evidence discovery platform that processes data from disparate sources such as social media using NLP and machine learning, producing analytics around patient-reported outcomes and real-world evidence for life sciences organizations.

Quantifiable outcome

• Successfully processed over 1 million pages and thousands of datasets for regulatory and voluntary submissions
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core and minor.

• VivlicoreStrategic or Co-development PartnerVivli is a non-profit organization home to an independent global data-sharing and analytics platform serving the international research community. RLS collaborates with Vivli to provide anonymization services for clinical trials, with Vivli acting as a neutral broker between data contributor and data user.
• ClaritiDoxminorImplementation/ SI/ Consulting PartnerClaritiDox is a team of experienced regulatory writers, editors, health literacy experts, and data anonymization specialists. They are recognized as a public benefit company promoting responsible sharing of study information. Partnership provides complementary document preparation and disclosure expertise.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Veeva Systems: Veeva is a major clinical and regulatory SaaS platform for life sciences, with Veeva Vault covering trial management, regulatory submissions, and quality — a broad incumbent that can bundle disclosure and anonymization features.
• Oracle Health Sciences: Oracle offers EDC (InForm), CTMS, safety, and analytics for clinical development; a broad incumbent that competes across the clinical trial technology stack and could expand into disclosure/redaction.

Direct peers

• TrialScope (Norstella): TrialScope provides clinical trial disclosure, transparency, and data-sharing solutions to sponsors and CROs, competing with RLS in the EMA/FDA disclosure and trial registration space.
• d-wise: d-wise provides clinical data standards, analytics, and anonymization services for life sciences R&D, sharing RLS's focus on CDISC-aligned clinical trial data and regulatory submission support.
• Privacy Analytics (IQVIA): Acquired by IQVIA, Privacy Analytics provides health data de-identification and anonymization software for clinical trials and health data sharing — directly comparable to RLS Protect's quantitative risk-based anonymization capability.
• SHYFT Analytics (Veeva): SHYFT was acquired by Veeva and provides clinical and commercial data analytics including disclosure and transparency solutions for pharma, overlapping with RLS's regulatory disclosure focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/real-life-sciences

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Real Life Sciences